AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23489912 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged stance test
Number of subjects: 0
Study 23489912 — intervention group
Group type: EXPERIMENTAL
Intervention: Snellen visual acuity test
Number of subjects: 0
Study 23489912 — intervention group
Group type: EXPERIMENTAL
Intervention: Marottoli method (functional neck range of motion)
Number of subjects: 0
Study 23489912 — intervention group
Group type: EXPERIMENTAL
Intervention: Whispered voice test
Number of subjects: 0
Study 23489912 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of motion and strength testing
Number of subjects: 0
Study 23490650 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-690514 (200mg daily)
Number of subjects: 90
Study 23490654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential arm S treated with 5-fluorouracil and leucovorin (LV5FU2) followed by FOLFOX (LV5FU2+oxaliplatin) and then FOLFIRI (LV5FU2+irinotecan)
Number of subjects: 410
Study 23490654 — intervention group
Group type: COMPARATOR
Intervention: Combination arm C that begins directly with FOLFOX followed by FOLFIRI
Number of subjects: 410
Study 23490654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential arm S
Number of subjects: 410
Study 23490654 — intervention group
Group type: COMPARATOR
Intervention: Combination arm C
Number of subjects: 410
Study 23490654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 410
Study 23491522 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c variability (measured as intraindividual SD of HbA1c values)
Number of subjects: 8260
Study 23491522 — intervention group
Group type: EXPERIMENTAL
Intervention: Average HbA1c (HbA1c-MEAN)
Number of subjects: 8260
Study 23491522 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HbA1c parameters (HbA1c-MEAN and HbA1c-SD) above the median
Number of subjects: 8260
Study 23491522 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HbA1c parameters (HbA1c-MEAN and HbA1c-SD) below the median
Number of subjects: 8260
Study 23493136 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally once daily combined with chemotherapy (5-fluorouracil, folinic acid, and either oxaliplatin or irinotecan)
Number of subjects: 45
Study 23493136 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally once daily combined with chemotherapy
Number of subjects: 45
Study 23493136 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib in combination with chemotherapy
Number of subjects: 45
Study 23493999 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ECD
Number of subjects: 72
Study 23493999 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower ECD at 6 months
Number of subjects: 72
Study 23493999 — intervention group
Group type: EXPERIMENTAL
Intervention: Coefficient of variation at 6 months
Number of subjects: 72
Study 23493999 — intervention group
Group type: EXPERIMENTAL
Intervention: HEX values at 6 months
Number of subjects: 72
Study 23493999 — intervention group
Group type: EXPERIMENTAL
Intervention: Most recent CV or HEX values
Number of subjects: 72
Study 23494041 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of omega-3 fatty acids daily (840 mg eicosapentaenoic acid/2520 mg docosahexaenoic acid) for 6 months
Number of subjects: 17
Study 23494984 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (600/100 mg twice daily)
Number of subjects: 75
Study 23494984 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model
Number of subjects: 75
Study 23494984 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian estimates of individual darunavir parameters and ritonavir
Number of subjects: 75
Study 23497046 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy for 1 month
Number of subjects: 67
Study 23497305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin™) in combination with XELOX or mFOLFOX6
Number of subjects: 150
Study 23497305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin™) in combination with FOLFIRI
Number of subjects: 150
Study 23497305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin™)
Number of subjects: 150
Study 23497334 — intervention group
Group type: COMPARATOR
Intervention: Alveolar macrophages (AMø) of smokers
Number of subjects: 61
Study 23497334 — intervention group
Group type: COMPARATOR
Intervention: Differentiated THP-1 cells exposed to cigarette smoke extract
Number of subjects: 61
Study 23497334 — intervention group
Group type: COMPARATOR
Intervention: Total lung macrophages from smokers
Number of subjects: 61
Study 23497334 — intervention group
Group type: COMPARATOR
Intervention: AMø of smokers stimulated with poly(I:C)
Number of subjects: 61
Study 23497336 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg daily
Number of subjects: 18
Study 23497336 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 100 mg daily
Number of subjects: 18
Study 23497336 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 150 mg daily
Number of subjects: 18
Study 23497336 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (any dose)
Number of subjects: 18
Study 23497336 — intervention group
Group type: COMPARATOR
Intervention: AI chemotherapy (without eltrombopag)
Number of subjects: 18
Study 23497349 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion therapy (4 × 10 Gy(RBE))
Number of subjects: 6
Study 23497365 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy; 30 mg/m² docetaxel on day 1 and 8, 60 mg/m² cisplatin on day 1, and 70 mg/m² S-1 on days 1 to 14, repeated every 21 days.
Number of subjects: 35
Study 23497415 — intervention group
Group type: EXPERIMENTAL
Intervention: V930 alone (Study 1)
Number of subjects: 33
Study 23497415 — intervention group
Group type: EXPERIMENTAL
Intervention: V930 followed by V932 (Study 2)
Number of subjects: 33
Study 23497455 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS 1 ng/kg intravenously
Number of subjects: 294
Study 23497524 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf muscle neuromuscular electrical stimulation (NMES)
Number of subjects: 11
Study 23497558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo tacrolimus perfusion at a concentration of 20 ng/ml in 1000 ml Custodiol solution
Number of subjects: 86
Study 23497558 — intervention group
Group type: COMPARATOR
Intervention: Placebo with Custodiol alone
Number of subjects: 86
Study 23497667 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-related problems (DRPs) identified in patients presenting with NSC
Number of subjects: 633
Study 23497667 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-related problems (DRPs)
Number of subjects: 633
Study 23497667 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy and certain drug classes (thiazides, antidepressants, benzodiazepines, anticonvulsants)
Number of subjects: 633
Study 23497731 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (12-week program with a minimum requirement of 17.5 kcal/kg weekly energy expenditure)
Number of subjects: 12
Study 23497731 — intervention group
Group type: EXPERIMENTAL
Intervention: Single exercise sessions
Number of subjects: 12
Study 23497790 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine XR 150 mg/day (monotherapy)
Number of subjects: 4
Study 23497790 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine XR 300 mg/day (monotherapy)
Number of subjects: 4
Study 23497790 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine XR 150 mg/day (adjunct therapy)
Number of subjects: 4
Study 23497790 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine XR 300 mg/day (adjunct therapy)
Number of subjects: 4
Study 23498300 — intervention group
Group type: EXPERIMENTAL
Intervention: TV viewing
Number of subjects: 307
Study 23499151 — intervention group
Group type: EXPERIMENTAL
Intervention: Office hysteroscopy
Number of subjects: 78
Study 23499577 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia treatment
Number of subjects: 0
Study 23499577 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 23500182 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of hip and trunk muscles
Number of subjects: 8
Study 23500218 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio)
Number of subjects: 51
Study 23500218 — intervention group
Group type: EXPERIMENTAL
Intervention: iFRa (iFR during adenosine administration)
Number of subjects: 51
Study 23500218 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR (fractional flow reserve)
Number of subjects: 51
Study 23500218 — intervention group
Group type: COMPARATOR
Intervention: Adenosine administration
Number of subjects: 51
Study 23500222 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed measurement (200-m course before discharge)
Number of subjects: 472
Study 23500222 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed tertiles (fastest, middle, slowest)
Number of subjects: 472
Study 23500222 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait speed (0.1 m/s increase)
Number of subjects: 472
Study 23500222 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of gait speed to FRS, B-type natriuretic peptide levels, and comorbidity index
Number of subjects: 472
Study 23500318 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted percutaneous coronary intervention using the CorPath 200 robotic system
Number of subjects: 164
Study 23500322 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily monitoring of B-type natriuretic peptide (BNP) levels for 60 days with a finger-stick test.
Number of subjects: 163
Study 23500412 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis
Number of subjects: 0
Study 23504355 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Safety Checklist (SSC) implementation
Number of subjects: 375
Study 23504398 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine at 45 mg/m² IV over 2 hours on day 1 and 15 and panitumumab 6 mg/kg IV over 1 hour on day 8 and 22 every 28 days
Number of subjects: 20
Study 23504398 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine and panitumumab combination
Number of subjects: 20
Study 23504807 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (8 mg/kg)
Number of subjects: 0
Study 23504807 — intervention group
Group type: COMPARATOR
Intervention: Intravenous trastuzumab (6 mg/kg)
Number of subjects: 0
Study 23505002 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandometer® intervention
Number of subjects: 143
Study 23505002 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led primary care clinic
Number of subjects: 143
Study 23505002 — intervention group
Group type: COMPARATOR
Intervention: Hospital clinic (control)
Number of subjects: 143
Study 23505034 — intervention group
Group type: EXPERIMENTAL
Intervention: High fitness level (based on estimated maximal oxygen consumption)
Number of subjects: 214
Study 23505034 — intervention group
Group type: COMPARATOR
Intervention: Low fitness level (based on estimated maximal oxygen consumption)
Number of subjects: 214
Study 23505034 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fitness levels
Number of subjects: 214
Study 23505034 — intervention group
Group type: COMPARATOR
Intervention: Lower fitness levels
Number of subjects: 214
Study 23505452 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low energy diet for 2 months
Number of subjects: 28
Study 23505452 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 10 months
Number of subjects: 28
Study 23506003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol metabolism assessment in critically ill patients
Number of subjects: 158
Study 23506003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol production measurement
Number of subjects: 158
Study 23506003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol clearance measurement during tracer infusion
Number of subjects: 158
Study 23506003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol clearance measurement after hydrocortisone administration
Number of subjects: 158
Study 23506003 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cortisol levels comparison
Number of subjects: 158
Study 23506003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol response to corticotropin stimulation
Number of subjects: 158
Study 23506003 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of urinary steroid ratios and liver biopsy samples
Number of subjects: 158
Study 23506243 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 800 mg qd, Atazanavir 600 mg qd, Lamivudine or Emtricitabine
Number of subjects: 17
Study 23506243 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir 400 mg bid, Atazanavir 600 mg qd, Lamivudine or Emtricitabine
Number of subjects: 17
Study 23506651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist scores on the attitudes subscale regarding the implementation of hypertension intervention
Number of subjects: 361
Study 23506651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist scores on the attitudes subscale regarding the implementation of asthma intervention
Number of subjects: 361
Study 23506651 — intervention group
Group type: COMPARATOR
Intervention: Clinical pharmacy service scores
Number of subjects: 361
Study 23506651 — intervention group
Group type: COMPARATOR
Intervention: TPB subscale scores
Number of subjects: 361
Study 23508216 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellofemoral pain syndrome (PFPS) group
Number of subjects: 57
Study 23508216 — intervention group
Group type: COMPARATOR
Intervention: Control group (no musculoskeletal pain)
Number of subjects: 57
Study 23509310 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine) for four cycles
Number of subjects: 117
Study 23509819 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic measures during a clinical diagnostic technique
Number of subjects: 2
Study 23510361 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive vagus nerve stimulation (nVNS)
Number of subjects: 4
Study 23510802 — intervention group
Group type: EXPERIMENTAL
Intervention: cediranib 20mg
Number of subjects: 599
Study 23511559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus gemcitabine (Schedule 2/1)
Number of subjects: 44
Study 23511678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration via nasal cannula at 5 L/min starting 15 minutes after SGB
Number of subjects: 38
Study 23511841 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-organ failure and multiorgan failure (MOF) in pediatric burn patients
Number of subjects: 821
Study 23511841 — intervention group
Group type: EXPERIMENTAL
Intervention: DENVER2 score for assessing organ-specific scores
Number of subjects: 821
Study 23511909 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS disorders
Number of subjects: 0
Study 23512637 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 30 μg/LNG 150 μg qd plus empagliflozin 25 mg qd for 7 days (test; period 2)
Number of subjects: 18
Study 23512637 — intervention group
Group type: COMPARATOR
Intervention: EE 30 μg/LNG 150 μg qd for 14 days (reference; period 1)
Number of subjects: 18
Study 23512786 — intervention group
Group type: COMPARATOR
Intervention: HIV/non-HCV recipients
Number of subjects: 116
Study 23512786 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HCV-coinfected recipients
Number of subjects: 116
Study 23512786 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 116
Study 23512786 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 count
Number of subjects: 116
Study 23512786 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV coinfection
Number of subjects: 116
Study 23512837 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT-A) injection
Number of subjects: 468
Study 23513068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 1134
Study 23513068 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexmedetomidine)
Number of subjects: 1134
Study 23513248 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 35
Study 23513248 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMV with set breathing frequencies of ≥ 10 breaths/min
Number of subjects: 35
Study 23513248 — intervention group
Group type: COMPARATOR
Intervention: Asynchronous subjects
Number of subjects: 35
Study 23514360 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily until objective tumor progression, unacceptable toxicity, death, or study discontinuation.
Number of subjects: 64
Study 23514360 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily
Number of subjects: 64
Study 23515007 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dietary fiber intake (highest quintiles)
Number of subjects: 491841
Study 23515007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intakes of legumes, whole grains, and cruciferous vegetables
Number of subjects: 491841
Study 23515007 — intervention group
Group type: COMPARATOR
Intervention: Refined grain intake (comparison of quintile 5 with quintile 1)
Number of subjects: 491841
Study 23515269 — intervention group
Group type: EXPERIMENTAL
Intervention: RTOG scale
Number of subjects: 55
Study 23515269 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCAE scale
Number of subjects: 55
Study 23515750 — intervention group
Group type: EXPERIMENTAL
Intervention: Core needle biopsy (CNB) using 20-gauge and 18-gauge semi-automated needles; 11 procedures under ultrasound guidance.
Number of subjects: 46
Study 23515750 — intervention group
Group type: EXPERIMENTAL
Intervention: Core needle biopsy (CNB)
Number of subjects: 46
Study 23515925 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 423
Study 23516391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dosing of foretinib (240 mg/day for 5 days every 2 weeks)
Number of subjects: 74
Study 23516391 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dosing of foretinib (80 mg/day)
Number of subjects: 74
Study 23516391 — intervention group
Group type: COMPARATOR
Intervention: Intermittent dosing of foretinib (240 mg/day)
Number of subjects: 74
Study 23516391 — intervention group
Group type: EXPERIMENTAL
Intervention: Foretinib treatment
Number of subjects: 74
Study 23516440 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg po daily for 24 weeks
Number of subjects: 35
Study 23517020 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose clopidogrel
Number of subjects: 0
Study 23517020 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose clopidogrel
Number of subjects: 0
Study 23517020 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*2 and *3 loss-of-function alleles
Number of subjects: 0
Study 23517449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal insulin delivery using a hollow microneedle
Number of subjects: 16
Study 23517449 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin delivery via insulin pump catheter
Number of subjects: 16
Study 23517836 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 435
Study 23517836 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting metallic stent (EES)
Number of subjects: 435
Study 23517836 — intervention group
Group type: EXPERIMENTAL
Intervention: BVS
Number of subjects: 435
Study 23517839 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting nitinol stents
Number of subjects: 108
Study 23518189 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccine (initial dose)
Number of subjects: 68
Study 23518218 — intervention group
Group type: EXPERIMENTAL
Intervention: NEVO SES
Number of subjects: 394
Study 23518218 — intervention group
Group type: COMPARATOR
Intervention: TAXUS PES
Number of subjects: 394
Study 23518262 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal Electrically Administered Seizure Therapy (FEAST)
Number of subjects: 17
Study 23518844 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron reduction (phlebotomy)
Number of subjects: 1262
Study 23518844 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1262
Study 23518869 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart-based indicators of palliative care
Number of subjects: 3065
Study 23518869 — intervention group
Group type: EXPERIMENTAL
Intervention: Family satisfaction
Number of subjects: 3065
Study 23518869 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-rated quality of dying
Number of subjects: 3065
Study 23518869 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-rated quality of dying
Number of subjects: 3065
Study 23518869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessments in the last 24 hours of life
Number of subjects: 3065
Study 23518869 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation of family conferences
Number of subjects: 3065
Study 23518869 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of prognosis in the first 72 hours in the ICU
Number of subjects: 3065
Study 23518928 — intervention group
Group type: EXPERIMENTAL
Intervention: TSPYL5 SNPs (rs1864729, rs2583506)
Number of subjects: 772
Study 23518928 — intervention group
Group type: EXPERIMENTAL
Intervention: TSPYL5 knockdown
Number of subjects: 772
Study 23518928 — intervention group
Group type: EXPERIMENTAL
Intervention: TSPYL5 overexpression
Number of subjects: 772
Study 23518928 — intervention group
Group type: EXPERIMENTAL
Intervention: LCLs with variant TSPYL5 SNP genotypes
Number of subjects: 772
Study 23518928 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromatin immunoprecipitation assay
Number of subjects: 772
Study 23519018 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR transgenic T cells targeted against MART-1
Number of subjects: 3
Study 23519018 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR-engineered ACT immunotherapy
Number of subjects: 3
Study 23519644 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention ('Obeldicks' program)
Number of subjects: 454
Study 23519724 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q ILA size 1.0
Number of subjects: 110
Study 23519724 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q ILA size 1.5
Number of subjects: 110
Study 23519724 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q ILA size 2.0
Number of subjects: 110